Lewandrowski K B, Medeiros L J, Harris N L
Department of Pathology, Massachusetts General Hospital, Boston.
Cancer. 1990 Sep 15;66(6):1158-64. doi: 10.1002/1097-0142(19900915)66:6<1158::aid-cncr2820660614>3.0.co;2-p.
The monoclonal antibody, 4F2, which reacts with an antigen expressed by activated and proliferating cells, was applied to frozen sections of nine reactive lymphoid lesions, 146 B-cell non-Hodgkin's lymphomas (NHL), and six plasmacytic neoplasms. In reactive cases, the 4F2 antigen was expressed by germinal center cells and interfollicular immunoblasts, the activated or proliferating lymphoid cells, and histiocytes. In the malignant cases, the 4F2 antigen was expressed by 94 (64%) B-cell NHL and all six plasma cell tumors. The incidence of positivity and intensity of expression loosely correlated with the three morphologic grades of NHL identified in the Working Formulation. Approximately one half of all low-grade lymphomas, two thirds of intermediate-grade lymphomas, and all high-grade lymphomas were 4F2 positive. Similarly, the mean intensity of 4F2 antigen expression increased with higher grade. However, for certain histologic subtypes, 4F2 antigen expression did not correlate with morphologic grade. For example, in the intermediate-grade category less than one half of diffuse small cleaved cell lymphomas were 4F2 positive, and expression was weak, similar to that of low-grade lymphomas. In contrast, all other histologic subtypes of lymphoma in the intermediate-grade category were strongly 4F2 positive. Expression of 4F2 antigen also correlated with plasmacytoid differentiation. Seventy-three percent of plasmacytoid small lymphocytic lymphomas (compared with 31% of cases of non-plasmacytoid small lymphocytic lymphoma/chronic lymphocytic leukemia) and all plasma cell neoplasms expressed the 4F2 antigen, the latter cases strongly.
单克隆抗体4F2可与活化及增殖细胞所表达的一种抗原发生反应，将其应用于9个反应性淋巴样病变、146例B细胞非霍奇金淋巴瘤（NHL）及6例浆细胞肿瘤的冰冻切片。在反应性病例中，4F2抗原由生发中心细胞、滤泡间免疫母细胞、活化或增殖的淋巴样细胞及组织细胞表达。在恶性病例中，94例（64%）B细胞NHL及所有6例浆细胞瘤表达4F2抗原。阳性发生率及表达强度与工作分类法中确定的NHL的三种形态学分级大致相关。所有低级别淋巴瘤中约一半、中级淋巴瘤的三分之二及所有高级别淋巴瘤均为4F2阳性。同样，4F2抗原表达的平均强度随分级升高而增加。然而，对于某些组织学亚型，4F2抗原表达与形态学分级无关。例如，在中级别的弥漫性小裂细胞淋巴瘤中，不到一半为4F2阳性，且表达较弱，与低级别淋巴瘤相似。相反，中级别淋巴瘤的所有其他组织学亚型均为4F2强阳性。4F2抗原的表达也与浆细胞样分化相关。73%的浆细胞样小淋巴细胞淋巴瘤（非浆细胞样小淋巴细胞淋巴瘤/慢性淋巴细胞白血病病例为31%）及所有浆细胞肿瘤均表达4F2抗原，后者表达较强。
